Therapy-related myeloid neoplasm

Summary

Therapy-related myeloid neoplasm (MONDO:0006450) is a cancer and 2 clinical trials. Top therapeutic interventions include nivolumab and gedatolisib. A subtype of myeloproliferative neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	therapy-related myeloid neoplasm
Mondo ID	MONDO:0006450
EFO	EFO:1000575
NCIT	C27912
GARD	0024414
Is cancer (heuristic)	yes

Also known as: acute myeloid Leukaemias and myelodysplastic syndromes, therapy-related · therapy-related acute myeloid leukaemia and myelodysplastic syndrome · therapy-related acute myeloid leukemia and myelodysplastic syndrome · therapy-related AML and MDS · therapy-related myeloid neoplasm · therapy-related myeloid neoplasms · TMN

Data availability: 6 cell lines.

Disease family

This is a subtype of myeloproliferative neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › myeloid neoplasm › myeloproliferative neoplasm › therapy-related myeloid neoplasm

Related subtypes (12): myeloid leukemia, essential thrombocythemia, myelodysplastic/myeloproliferative neoplasm, transient myeloproliferative syndrome, primary myelofibrosis, myeloproliferative disease, autosomal recessive, thrombocytopenia 6, chronic eosinophilic leukemia, chronic neutrophilic leukemia, myeloproliferative neoplasm, unclassifiable, erythroid neoplasm, myelofibrosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Nivolumab	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02438761	PHASE2	TERMINATED	PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)
NCT02532231	PHASE2	COMPLETED	Nivolumab in AML in Remission at High Risk for Relapse

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NIVOLUMAB	4	1
GEDATOLISIB	3	1